In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Executive Director, Darius Lakdawalla, and Anupam Jena recommend that creators of value frameworks recognize the unique issues associated with valuing treatments for rare diseases by adopting societal, as well payer-oriented perspectives. Included in this assessment are the important roles of treatment spillovers, societal preferences about health equity, and the insurance value of innovation.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
